Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E-therapeutics Adds New Board Member

This article was originally published in Scrip

Executive Summary

E-Therapeutics PLC. has appointed Trevor Mervyn Jones as non-executive director. Rajesh Chopra will be resigning as non-executive director to return to academic research. Currently Jones is chair of the international clinical research organisation (CRO), Simbec-Orion Group Ltd. and Welsh investment company, Arthurian Life Sciences Ltd. Previously he was director of Allergan Inc. and R&D director of The Wellcome Foundation and has also held advisory and regulatory roles. He was director general of the Association of the British Pharmaceutical Industry (ABPI), board member of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). Jones was also a member of the UK government regulatory agency, The Medicines Commission for 12 years.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel